HCM HCM
Company Profile ↓Company Overview
HCM (HCM) is a publicly traded company listed on with a market capitalization of $10.08B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 36.9%, reflecting efficient use of shareholder capital.
Trades at an undemanding P/E of 4.4.
Maintains a net profit margin of 83.3%.
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- Dec 2025 Revenue of $548.51M (-13.0% YoY); net profit $456.91M.
- Trailing 12 Months Year-on-year growth — revenue -13.0%, earnings +1111.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.76% |
| 1 Year: | -12.96% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 1,111.03% |
Stock Price Performance
| 1 Year: | -35.56% |
| 6 Months: | -19.74% |
| 3 Months: | -13.16% |
| 1 Month: | +4.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.02 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 36.9%.
- Excellent profit margin of 83.3%.
CONS
- Trading 35.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 426.41M | 838.00M | 630.20M | 548.51M |
| Cost of Revenue | - | 311.10M | 384.45M | 348.88M | 336.35M |
| Gross Profit | - | 115.31M | 453.55M | 281.32M | 212.16M |
| Operating Expenses | - | 521.57M | 432.04M | 321.93M | 247.86M |
| Operating Income | - | -406.26M | 21.51M | -40.61M | -35.70M |
| EBITDA | - | -401.11M | 67.27M | 14.11M | 514.86M |
| Interest Expense | - | 652.00K | 759.00K | 2.87M | 2.87M |
| Pretax Income | - | -410.42M | 58.31M | -1.11M | 498.69M |
| Tax Provision | - | -283.00K | 4.51M | 7.19M | 63.61M |
| Net Income | - | -360.83M | 100.78M | 37.73M | 456.91M |
| Diluted EPS | - | -2.15 | 0.60 | 0.20 | 2.65 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.03B | 1.28B | 1.27B | 1.75B |
| Current Assets | - | 839.89M | 1.10B | 1.07B | 1.57B |
| Cash & Equivalents | - | 313.28M | 283.59M | 153.96M | 71.33M |
| Inventory | - | 56.69M | 50.26M | 50.40M | 41.13M |
| Receivables | - | 97.99M | 116.89M | 155.54M | 126.75M |
| Total Liabilities | - | 392.57M | 536.39M | 502.34M | 501.83M |
| Current Liabilities | - | 353.90M | 403.03M | 376.56M | 315.77M |
| Long Term Debt | - | 18.10M | 48.19M | 59.43M | 68.19M |
| Total Debt | - | 27.01M | 86.13M | 89.82M | 97.89M |
| Total Equity | - | 610.37M | 730.54M | 759.93M | 1.24B |
| Shares Outstanding | - | 864.78M | 871.26M | 871.60M | 872.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -268.60M | 219.26M | 497.00K | -64.66M |
| Investing Cash Flow | - | 296.59M | -291.14M | -96.06M | -29.41M |
| Financing Cash Flow | - | -82.76M | 48.66M | -30.67M | 7.84M |
| Capital Expenditure | - | -36.66M | -32.61M | -17.93M | -24.15M |
| Free Cash Flow | - | -305.26M | 186.65M | -17.44M | -88.81M |
| Net Change in Cash | - | -54.77M | -23.22M | -126.23M | -86.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 27.0% | 54.1% | 44.6% | 38.7% |
| Operating Margin % | - | -95.3% | 2.6% | -6.4% | -6.5% |
| Net Margin % | - | -84.6% | 12.0% | 6.0% | 83.3% |
| ROE % | - | -59.1% | 13.8% | 5.0% | 36.9% |
| ROCE % | - | -60.1% | 2.5% | -4.5% | -2.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HCM
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTE9BZjRnUmthVjdWWFJDY2EydE5kSkpIOXRNUzRyLXE3VUZNdjJYQVZhcFdpUHJfcF9VbmczdzZZalYwMm5vNWdzak13X2F1X3M?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <font…
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQLVpXdWp1VUhQdTJwbjB3Z2l5NlBtQXZ0Rk1IYkcwMlZGeDVIVXVxNlY4NjA0alJuRTNLZEdVVFQ2bFA5SlkxUmpWWXJHTW1XeUlZbC1aZnFsdG5KUW1aT1JlcFRHY3NrRWNZT1g0WkhKWEpfc2NMRDRkX3llRXhIT2ttbmYyZ0kwT18wc0…
HUTCHMED’s FRUZAQLA approved or launched in 41 countries - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPLWVxTFJYemFKcDVuQ0NWSENWVUxGeF9FY3B1Q3Q4LW50dnpOZVhLR0xveFZjaFNTcHBxRzNyUGhBXzZWWk5GLV9CSEZybXczNzNiZmpyYUlPcmN6dVhUdFVFS1dkY0VpQTFfejlSZWtoQVZGb3lIZHhKZElVUTdjNm4xRHFtaVlScjQ4?o…
How Hcm Defender 100 Index Etf (QQH) Affects Rotational Strategy Timing - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQelN1ZmNKWGt4NW5wZTF6Q3JpWm1OdjNhaFpVM0h2MklxaDhUZ2tjZzJjT0ZzNEZzUE1MYUd0Q0JOWXhsRDAxM2YzbXV3aF9kcGFpRDVaUmNSd2QyRi1QRFptS25zWnExZWRGMVhsczlkMlhFUE9SWTFFX2tSQklXSkZScmRFaW5jTUR6Q1…
Edgewise stock yo-yos after Phase II data release for HCM candidate - FirstWord Pharma
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFB5ZEdOazhBYVVscTZOdTA1ZGt5OU9hemZzU2VIWVU2cExRMEFHNUJsdlFDdHgyZ2tZWDFzb0JpeE8wNmYxcldCWXhSeUtwUUZOM3M4?oc=5" target="_blank">Edgewise stock yo-yos after Phase II data release for H…
HUTCHMED (NASDAQ:HCM) Announces Earnings Results - MarketBeat
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOclVENlgzcmJoVkV0T3NDLUZPa2UtYUdCNXZMRWN3RHZlSlJ1VkZMdXloajFEaTREc2dYUGJOeVB0V2NjS0h4VnZzZzBDZlp6TllTWnlpSHdoLUUyT3FDT0M0RmNCbVQzRlBjYzZPaWxJaUZEbGZOSTRQOWlzbHZYWFBZVmtGcTNpcGJhX3…
HCM — Frequently Asked Questions
What is the current share price of HCM?
As of 2026-08-05 17:25 PDT, HCM trades at $11.55 on NASDAQ/NYSE. Its 52-week range is $9.99 to $17.93.
What is the market capitalisation of HCM?
HCM has a market capitalisation of $10.08B on NASDAQ/NYSE.
What is the P/E ratio of HCM?
HCM trades at a trailing price-to-earnings (P/E) ratio of 4.36. Its price-to-book (P/B) ratio is 8.14.
What is the return on equity (ROE) of HCM?
HCM has a return on equity (ROE) of 36.91%. Its return on capital employed (ROCE) is -2.48%.
Is HCM a good stock to buy?
This page provides a data-driven analysis of HCM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.